Cart (0 Items)
Your cart is currently empty.
View ProductsProprietary Antibody librairies
Innovative tools for your success
Contact us Talk to our experts
0
Proprietary librairies
0ʳˢᵗ
Human cancer & COVID-19 libraries in the world
0¹⁰
Estimated clones per library
We develop ground-breaking resources to support your success
Success Begins with the Right Library
In phage display and antibody discovery, the quality and origin of the repertoire dictate:
- The diversity of accessible antibodies
- Functional and biological relevance
- Future developability
- The speed at which leads are obtained
- The specie
A poor antibody library can limit your success, slowing down discoveries and restricting your options.
Pioneering phage display librairies
ProteoGenix is dedicated to provide tailored services relevant for your application. That is why we developed the world’s first COVID library and Cancer library.
Always improving
We continuously improve our libraries to improve clinical relevance and diversity. In a recent update, our cancer library went from 7 to 18 types of cancer, including rare ones.
Our immune libraries developed to fulfill our clients’ needs
LiAb-SFCOVID-19TM Library
Human – Donors who recovered from COVID-19.
Application: Ideal for COVID-19 antibody generation
Format: ScFv
Size: 1.19 x 1010 clones
LiAb-SFCANCERTM Library
Human – PBMCs & BMMCs from Human Donors. 18 different cancers.
Application: Ideal for custom cancer immunotherapy development
Format: ScFv & Fab
Size: 6.81×1010 ScFv & 6.72×1010 Fab
LiAb-SFAUTOIMMTM Library
Human – PBMCs & BMMCs from Human Donors. 12 different autoimmune diseases.
Application: Ideal for custom cancer immunotherapy development
Format: ScFv & Fab
Size: 1.08×1011 ScFv & 1.06×1011 Fab
Naïve Libraries for Maximum Versatility
Confidently Launch Your Project with Librairies Tailored to your Application
-
Our diverse multi-species libraries, including fully human, or animal health repertoires (dog, cat, pig…), offer the flexibility to find the ideal biological match for your needs.
-
-
-
Research Powered by ProteoGenix
Publications
González, N. K., Otero, M. J., Puig, R. V., Amill, L. P., Santos, C. J. R. D., Soc, G. T. L., La Recerca Biomedica Fcrb, F. C. P. A., De Barcelona, H. C., & Sunyer, I. D. B. a. P. I. (2022, January 5). EP4209511A1 – Anti-cd84 antibodies amd chimeric antigen receptors – Google Patents.
Read here
Publications
Simons, M., & Corti, F. (2020, May 22). WO2021237159A1 – Methods and compositions to treat vascular leak – Google Patents.
Read here
Publications
Christlmeier, M., Kraller, M., Holthoff, H., Ungerer, M., Simmnacher, K., & GmbH, I. B. (2023, January 30). WO2024160736A1 – Human anti-trem2 antibody for treating neurodegenerative disorders – Google Patents.
Read here
Publications
Messer, J. (2023, June 7). WO2024254399A2 – Anti-toh1 antibodies and methods of use thereof – Google Patents.
Read here
Publications
Signorile, P. G., & Individual. (2023, September 19). WO2025062271A1 – Antibodies against endometriosis – Google Patents.
Read here
Publications
Vigo, M., Placci, M., & Muro, S. (2024). Isoform-specific vs. isoform-universal drug targeting: a new targeting paradigm illustrated by new anti-ICAM-1 antibodies. Journal of Drug Targeting, 33(4), 562–574.
Read here
Publications
Pitaro, M., Antonini, G., Arcovito, A., Buccisano, F., De Lauro, A., Consalvo, M. I., Gallo, V., Giacon, N., Mangiatordi, G. F., Pacelli, M., Pitaro, M. T., Polticelli, F., Sorrenti, M., & Venditti, A. (2024). Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Frontiers in Immunology, 15, 1520103.
Read here
Publications
Vidal-Calvo, E. E., Martin-Salazar, A., Choudhary, S., Dagil, R., Raghavan, S. S. R., Duvnjak, L., Nordmaj, M. A., Clausen, T. M., Skafte, A., Oberkofler, J., Wang, K., Agerbæk, M. Ø., Løppke, C., Jørgensen, A. M., Ropac, D., Mujollari, J., Willis, S., López, A. G., Miller, R. L., . . . Salanti, A. (2024). Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nature Communications, 15(1), 7553.
Read here
Publications
Ong, J. C., Zhao, J. J., Liu, Y., Srivastava, S., Chia, D. K. A., Quek, Y. E., Fan, X., Ma, H., Huang, K. K., Sheng, T., Tan, Q. X., Ng, G., Tan, J. W. S., Lee, J. J., Loo, L., Chong, L. Y., Ong, X. W., Tay, S. T., Hagihara, T., . . . Sundar, R. (2025). Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis. Clinical Cancer Research, 31(12), 2515–2529.
Read here
Publications
Rouis, O. (2024, December 11). Accelerating Translational Research: How Phage Display Technology delivered High-Affinity Antibodies for Groundbreaking applications. ProteoGenix.
Read here
Ready to take the next step?
Explore our custom antibody services or contact our Experts.
Contact us Custom Antibody Services Custom Phage Display Services
